SCHEDULE: MeiraGTx Repurchases Shares from Perceptive Master Fund

MeiraGTx Holdings plc executed an $18.19 million share repurchase from Perceptive Life Sciences Master Fund, reducing Perceptive's stake to 12.9%.

Summary

• MeiraGTx Holdings plc repurchased 2,300,000 Ordinary Shares from Perceptive Life Sciences Master Fund, Ltd. on December 31, 2025.
• The repurchase price was $7.91 per share, totaling an aggregate purchase price of $18,193,000.
• The $7.91 per share price was the volume-weighted average price (VWAP) on the Nasdaq Global Select Market on December 31, 2025.
• Following the transaction, Perceptive Life Sciences Master Fund, Ltd. and its affiliates beneficially own 10,441,562 Ordinary Shares, representing 12.9% of the outstanding class.
• This transaction reduced Perceptive's ownership from an approximate 15.83% stake to 12.9%.
• The Master Fund and its affiliates entered into a 12-month lock-up agreement, restricting the sale or transfer of their remaining Ordinary Shares from the closing date, with certain exceptions.
• The transaction is expected to close on January 5, 2026.

Sentiment

Score: 6

Explanation: The share repurchase at VWAP is a positive for remaining shareholders, reducing share count and potentially boosting EPS. However, the significant reduction in stake by a major institutional investor like Perceptive could be viewed with caution, despite the accompanying lock-up agreement.

Positives

• The share repurchase can be viewed as a positive signal, indicating management's belief that the stock is undervalued and aims to enhance shareholder value by reducing the outstanding share count.
• The repurchase was executed at the market's volume-weighted average price, suggesting a fair valuation for the transaction.
• The 12-month lock-up agreement provides stability regarding a significant portion of the remaining institutional holding, limiting immediate selling pressure from Perceptive.

Negatives

• A major institutional investor, Perceptive Life Sciences Master Fund, Ltd., significantly reduced its stake in the company, which could be interpreted negatively by the market.
• The reduction in Perceptive's ownership from approximately 15.83% to 12.9% represents a substantial divestment by a key shareholder.

Risks

• No specific new risks are introduced in this Schedule 13D amendment beyond the potential market perception implications of a large investor reducing its stake.

Future Outlook

The filing indicates a 12-month lock-up period for Perceptive's remaining shares, suggesting a period of stability regarding this significant institutional holding, with exceptions for certain corporate actions or transfers to affiliates.

Management Comments

• No direct quotes or paraphrased statements from company management are provided in this Schedule 13D filing, which primarily details an ownership change and related agreement.

Industry Context

Share repurchases are a common strategy for companies to return capital to shareholders and can signal management's confidence in the company's valuation. For a biotechnology company like MeiraGTx, such a move, especially involving a significant institutional investor like Perceptive, could be viewed in various ways by the market, depending on the company's broader strategic goals and financial health. The reduction in a major investor's stake might raise questions about their long-term conviction, even if the repurchase itself is a positive for remaining shareholders.

Comparison to Industry Standards

• No specific comparisons to industry benchmarks or comparable companies, projects, or results are provided within this Schedule 13D filing. The transaction is an internal corporate finance event.

Related Party Transactions

• The share repurchase involves the Issuer buying shares from Perceptive Life Sciences Master Fund, Ltd., a significant shareholder, which can be considered a related party transaction due to Perceptive's substantial ownership and potential influence.

Stakeholder Impact

• Shareholders: Remaining shareholders may benefit from a reduced share count, potentially increasing earnings per share and share value. However, the reduction in a major institutional investor's stake might lead to market uncertainty.
• Company (MeiraGTx): Utilizes cash to reduce outstanding shares, which can improve financial metrics like earnings per share.
• Perceptive Life Sciences Master Fund, Ltd.: Monetizes a portion of its investment in MeiraGTx.

Next Steps

• The Share Repurchase transaction is expected to close on January 5, 2026.
• The Master Fund and its affiliates are subject to a 12-month lock-up period from the closing date for their remaining Ordinary Shares, with specific exceptions.

Key Dates

Recommendation

While the share repurchase is a positive signal for capital allocation and can support share price, the reduction in a significant institutional stake by Perceptive Advisors warrants a cautious 'hold' stance. Investors should monitor the company's strategic direction and financial performance post-repurchase to assess the long-term implications of this ownership change.

Keywords

MeiraGTx Holdings, Perceptive Advisors, Share Repurchase, SEC Filing, Schedule 13D, Institutional Ownership, Stock Buyback, Biotechnology, Gene Therapy